Literature DB >> 23846765

Topical glaucoma therapy cost in Mexico.

Gabriel Lazcano-Gomez1, Alejandra Hernandez-Oteyza, María José Iriarte-Barbosa, Carlos Hernandez-Garciadiego.   

Abstract

Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α(2)-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846765     DOI: 10.1007/s10792-013-9823-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  22 in total

1.  Comparison of annual cost between brand and generic ocular beta-adrenergic blockers.

Authors:  Hiroaki Ikeda; Hidetoshi Tsukamoto; Akihiro Sawa; Ayako Sugimoto; Hiromu Mishima; Kenji Kihira
Journal:  Yakugaku Zasshi       Date:  2005-05       Impact factor: 0.302

2.  [Economic impact of eyedrop cost in glaucoma treatment].

Authors:  Iane Gonçalves Stillitano; Manoel Gonçalves de Lima; Marco Polo Ribeiro; Juliana Cabral; Carlos Teixeira Brandt
Journal:  Arq Bras Oftalmol       Date:  2005-03-30       Impact factor: 0.872

3.  Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe.

Authors:  C E Traverso; J G Walt; S P Kelly; A H Hommer; A M Bron; P Denis; J-P Nordmann; J-P Renard; A Bayer; F Grehn; N Pfeiffer; C Cedrone; S Gandolfi; N Orzalesi; C Nucci; L Rossetti; A Azuara-Blanco; A Bagnis; R Hitchings; J F Salmon; G Bricola; P M Buchholz; S V Kotak; L M Katz; L R Siegartel; J J Doyle
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 4.  An assessment of the health and economic burdens of glaucoma.

Authors:  Rohit Varma; Paul P Lee; Ivan Goldberg; Sameer Kotak
Journal:  Am J Ophthalmol       Date:  2011-10       Impact factor: 5.258

5.  A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

Authors:  Paul P Lee; John G Walt; John J Doyle; Sameer V Kotak; Stacy J Evans; Donald L Budenz; Philip P Chen; Anne L Coleman; Robert M Feldman; Henry D Jampel; L Jay Katz; Richard P Mills; Jonathan S Myers; Robert J Noecker; Jody R Piltz-Seymour; Robert R Ritch; Paul N Schacknow; Janet B Serle; Gary L Trick
Journal:  Arch Ophthalmol       Date:  2006-01

6.  The economic burden of major adult visual disorders in the United States.

Authors:  David B Rein; Ping Zhang; Kathleen E Wirth; Paul P Lee; Thomas J Hoerger; Nancy McCall; Ronald Klein; James M Tielsch; Sandeep Vijan; Jinan Saaddine
Journal:  Arch Ophthalmol       Date:  2006-12

7.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

8.  Daily cost of glaucoma medications in China.

Authors:  Ying Gao; Lingling Wu; Aijun Li
Journal:  J Glaucoma       Date:  2007 Oct-Nov       Impact factor: 2.503

9.  Severity of visual field loss and health-related quality of life.

Authors:  Roberta McKean-Cowdin; Rohit Varma; Joanne Wu; Ron D Hays; Stanley P Azen
Journal:  Am J Ophthalmol       Date:  2007-04-02       Impact factor: 5.258

10.  Cost Analysis of Medical versus Surgical Management of Glaucoma in Nigeria.

Authors:  Afekhide E Omoti; Omolabake T Edema; Benedicta A Akpe; Patricia Musa
Journal:  J Ophthalmic Vis Res       Date:  2010-10
View more
  3 in total

1.  A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery.

Authors:  Peter Y Zhao; Raheem Rahmathullah; Brian C Stagg; Faisal Almobarak; Deepak P Edward; Alan L Robin; Joshua D Stein
Journal:  JAMA Ophthalmol       Date:  2018-11-01       Impact factor: 7.389

2.  A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma.

Authors:  Francisco Gómez-Aguayo; José A Paczka; Rubén Leñero-Córdova; Jesús Jiménez-Román; Jaime Davila-Villarreal; Curt Hartleben; Leopoldo Baiza-Durán; Oscar Olvera-Montaño; Francisco García-Velez; Patricia Muñoz-Villegas
Journal:  Ophthalmol Ther       Date:  2018-04-21

3.  Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.

Authors:  Gabriel Lazcano-Gomez; Daniela Alvarez-Ascencio; Cindy Haro-Zuno; Mauricio Turati-Acosta; Magdalena Garcia-Huerta; Jesus Jimenez-Arroyo; Rafael Castañeda-Diez; Armando Castillejos-Chevez; Roberto Gonzalez-Salinas; Francisca Dominguez-Dueñas; Jesus Jimenez-Roman
Journal:  J Curr Glaucoma Pract       Date:  2017-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.